Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation
Authors:
Open Access
- 9 April 2022
- journal article
- research article
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 27 (4) , 337-351
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (15K20099, 17K11202)
This publication has 44 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Role of Hsp90 in Systemic Lupus Erythematosus and Its Clinical RelevanceAutoimmune Diseases, 2012
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibitionBlood, 2010
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesEuropean Journal of Cancer, 2010
- Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activationMolecular Immunology, 2009
- HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cellsCell Communication and Signaling, 2009
- Targeting HSP90 for cancer therapyBritish Journal of Cancer, 2009
- Targeting Hsp90: small-molecule inhibitors and their clinical developmentCurrent Opinion in Pharmacology, 2008
- The Banff 2007 Working Classification of Skin-Containing Composite Tissue Allograft PathologyAmerican Journal of Transplantation, 2008